SCNI — SCINAI IMMUNOTHERAPEUTICS LT
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — |
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 6 SEC-registered investment managers reported holding SCNI (SCINAI IMMUNOTHERAPEUTICS LT) in their latest 13F filings, with a combined reported value of $75.40K across 53.74K shares. That is -38.9% by share count (-34.18K shares) versus the previous quarter, while reported value moved +240.3%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 2 opened new positions, 1 added to existing stakes, 3 trimmed, 6 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of SCINAI IMMUNOTHERAPEUTICS LT (SCNI) include Yorkville Advisors Global, LP, SABBY MANAGEMENT, LLC, HRT FINANCIAL LP, ranked by reported 13F value among the 26 institutional holders on this page.
SCNI is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 6 | 53.74K | $75.40K | -38.9% |
| Q2 2026 | 10 | 189.19K | $49.08K | +27.5% |
| Q1 2026 | 4 | 26.90K | $14.88K | -13.2% |
| Q4 2025 | 7 | 81.95K | $58.38K | +17.4% |
| Q3 2025 | 6 | 48.13K | $60.88K | +18.4% |
| Q2 2025 | 6 | 79.39K | $181.27K | -5.7% |
| Q1 2025 | 4 | 16.80K | $45.20K | -34.0% |
| Q4 2024 | 4 | 25.44K | $85.06K | +1184.7% |
Over the 8 quarters shown, institutional share counts increased 111% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q4 2024 (+1184.7%).
Top Institutional Holders (Q3 2026) — 6 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 31.62K | $44.00K | 0.00% | Add | |
| 20.76K | $29.48K | 0.00% | Reduce | |
| 1.35K | $1.91K | 0.00% | Reduce | |
| 5 | $7 | 0.00% | Reduce | |
| 2 | $3 | 0.00% | New | |
| 1 | $1 | 0.00% | New |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 10 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 62.26K | $15.73K | 0.00% | New | |
| 35.94K | $9.08K | 0.00% | New | |
| 19.48K | $5.00K | 0.00% | New | |
| 13.09K | $4.56K | 0.00% | New | |
| 16.76K | $4.24K | 0.00% | Reduce | |
| 13.51K | $3.42K | 0.00% | Add | |
| 12.04K | $3.04K | 0.00% | New | |
| 12.09K | $3.00K | 0.00% | New | |
| 3.96K | $1.00K | 0.00% | Add | |
| 58 | $15 | 0.00% | Hold |
Q1 2026 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 24.04K | $13.28K | 0.00% | Reduce | |
| 1.88K | $1.04K | 0.00% | Hold | |
| 919 | $524 | 0.00% | Reduce | |
| 58 | $33 | 0.00% | Hold |
Q4 2025 — 7 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 34.56K | $24.61K | 0.00% | Add | |
| 27.29K | $19.44K | 0.00% | New | |
| 15.41K | $11.00K | 0.00% | New | |
| 1.88K | $1.33K | 0.00% | Reduce | |
| 1.75K | $1.25K | 0.00% | Add | |
| 1.00K | $712 | 0.00% | Hold | |
| 58 | $41 | 0.00% | Reduce |
Q3 2025 — 6 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 28.63K | $36.22K | 0.00% | Add | |
| 14.70K | $18.59K | 0.00% | New | |
| 3.55K | $4.49K | 0.00% | Add | |
| 1.00K | $1.26K | 0.00% | New | |
| 245 | $310 | 0.00% | Reduce | |
| 8 | $10 | 0.00% | Reduce |
Q2 2025 — 6 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 42.00K | $95.76K | 0.06% | New | |
| 12.06K | $27.49K | 0.00% | Reduce | |
| 11.60K | $26.56K | 0.00% | New | |
| 10.00K | $22.90K | 0.00% | New | |
| 3.48K | $7.97K | 0.00% | Add | |
| 255 | $581 | 0.00% | Hold |
New Positions (Q3 2026)
- JPMorgan Chase & Co 2 sh · $3
- DANSKE BANK A/S 1 sh · $1
Fully Exited (vs previous quarter)
- ARMISTICE CAPITAL, LLC sold 35.94K sh · $9.08K
- Virtu Financial LLC sold 19.48K sh · $5.00K
- StoneX Group Inc. sold 13.09K sh · $4.56K
- XTX Topco Ltd sold 16.76K sh · $4.24K
- CAPTRUST FINANCIAL ADVISORS sold 12.04K sh · $3.04K
- UBS Group AG sold 3.96K sh · $1.00K
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 31.62K | 12.09K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Citadel Advisors | 20.76K | 62.26K | — | 34.56K | 28.63K | 11.60K | — | — | — | — | 12.21K | — | — | — | — | 17.46K |
| RHUMBLINE ADVISERS | 1.35K | 13.51K | 1.88K | 1.88K | 3.55K | 3.48K | 1.57K | 1.65K | 1.65K | 1.14K | 6.65K | 5.31K | 3.55K | — | — | — |
| Morgan Stanley | 5 | 58 | 58 | 58 | 245 | 255 | 255 | 255 | 255 | 255 | 2.58K | 2.58K | 2.28K | 2.18K | 2.26K | 2.82K |
| JPMorgan Chase & Co | 2 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| DANSKE BANK A/S | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SABBY MANAGEMENT, LLC | — | — | — | — | — | — | — | — | — | 17.83K | 253.13K | 220.66K | 244.97K | — | — | — |
| ARMISTICE CAPITAL, LLC | — | 35.94K | — | — | — | — | — | — | — | — | 121.78K | 230.90K | 362.45K | — | — | — |
| Yorkville Advisors Global, LP | — | — | — | — | — | 42.00K | — | — | — | — | — | — | — | — | — | — |
| UBS Group AG | — | 3.96K | 919 | 1.75K | 8 | 12.06K | 14.93K | 23.49K | 30 | 211 | 2.12K | 2.12K | 824 | 306 | 5.32K | 300 |
| BANK OF MONTREAL /CAN/ | — | — | — | — | — | 10.00K | — | — | — | — | — | — | — | — | — | — |
| XTX Topco Ltd | — | 16.76K | 24.04K | 27.29K | — | — | — | — | — | — | — | — | — | — | — | — |
| TWO SIGMA SECURITIES, LLC | — | — | — | — | 14.70K | — | — | — | — | — | — | — | — | — | — | — |
| Virtu Financial LLC | — | 19.48K | — | 15.41K | — | — | — | — | — | — | — | — | — | — | — | — |
| MILLENNIUM MANAGEMENT LLC | — | — | — | — | — | — | — | — | — | — | 10.61K | — | — | — | — | — |
| StoneX Group Inc. | — | 13.09K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CAPTRUST FINANCIAL ADVISORS | — | 12.04K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | — | — | — | 1.00K | 1.00K | — | — | — | — | — | — | — | — | — | — | — |
| Bank of America Corp | — | — | — | — | — | — | — | — | — | 100 | — | — | — | — | — | — |
| CREDIT AGRICOLE S A | — | — | — | — | — | — | 42 | 42 | 42 | — | 424 | 424 | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold SCNI?
As of 2026-Q3, 6 institutional funds reported holding SCNI (SCINAI IMMUNOTHERAPEUTICS LT) in SEC 13F filings, with a combined reported value of $75.40K.
How many shares of SCNI do institutions own?
13F filers reported 53.74K shares of SCNI, worth $75.40K in aggregate at the end of 2026-Q3.
Is institutional ownership of SCNI rising or falling?
Share counts moved -38.9% versus the prior quarter — distribution.
Who are the top institutional holders of SCNI?
The largest 13F holders are Yorkville Advisors Global, LP, SABBY MANAGEMENT, LLC, HRT FINANCIAL LP, Citadel Advisors, BANK OF MONTREAL /CAN/; the top 25 are ranked at the top of this page.
Who are the major shareholders of SCINAI IMMUNOTHERAPEUTICS LT?
The major shareholders of SCINAI IMMUNOTHERAPEUTICS LT (SCNI) by reported 13F value are Yorkville Advisors Global, LP, SABBY MANAGEMENT, LLC, HRT FINANCIAL LP, Citadel Advisors, BANK OF MONTREAL /CAN/, among 26 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.